Recurrent activating mutations of PPARγ associated with luminal bladder tumors

Archive ouverte

Rochel, Natacha | Krucker, Clémentine | Coutos-Thévenot, Laure | Osz, Judit | Zhang, Ruiyun | Guyon, Elodie | Zita, Wayne | Vanthong, Séverin | Hernandez, Oscar Alba | Bourguet, Maxime | Badawy, Kays Al | Dufour, Florent | Peluso-Iltis, Carole | Heckler-Beji, Syrine | Dejaegere, Annick | Kamoun, Aurélie | de Reyniès, Aurélien | Neuzillet, Yann | Rebouissou, Sandra | Béraud, Claire | Lang, Hervé | Massfelder, Thierry | Allory, Yves | Cianférani, Sarah | Stote, Roland, H. | Radvanyi, François | Bernard-Pierrot, Isabelle

Edité par CCSD ; Nature Publishing Group -

International audience. The upregulation of PPARγ/RXRα transcriptional activity has emerged as a key event in luminal bladder tumors. It renders tumor cell growth PPARγ-dependent and modulates the tumor microenvironment to favor escape from immuno-surveillance. The activation of the pathway has been linked to PPARG gains/amplifications resulting in PPARγ overexpression and to recurrent activating point mutations of RXRα. Here, we report recurrent mutations of PPARγ that also activate the PPARγ/RXRα pathway, conferring PPARγ-dependency and supporting a crucial role of PPARγ in luminal bladder cancer. These mutations are found throughout the protein-including N-terminal, DNA-binding and ligand-binding domains-and most of them enhance protein activity. Structure-function studies of PPARγ variants with mutations in the ligand-binding domain allow identifying structural elements that underpin their gain-of-function. Our study reveals genomic alterations of PPARG that lead to pro-tumorigenic PPARγ/RXRα pathway activation in luminal bladder tumors and may open the way towards alternative options for treatment.

Suggestions

Du même auteur

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies

Archive ouverte | Lang, Hervé | CCSD

International audience. Background Muscle-invasive bladder cancer (MIBC) and upper urinary tract urothelial carcinoma (UTUC) are molecularly heterogeneous. Despite chemotherapies, immunotherapies, or anti-fibroblast...

PPARγ is a tumor suppressor in basal bladder tumors offering new potential therapeutic opportunities

Archive ouverte | Coutos-Thévenot, Laure | CCSD

PPARactivation is a critical event in luminal muscle-invasive bladder cancer (MIBC) tumorigenesis, favoring both tumor cell growth and microenvironment modulation toward tumor immune escape. Conversely, the do...

Abstract A24: Establishment of a panel of patient-derived tumor xenograft models recapitulating molecular heterogeneity and drug response of muscle-invasive bladder tumors

Archive ouverte | Béraud, Claire | CCSD

International audience. Abstract Background: Muscle-invasive bladder cancers (MIBCs) constitute a heterogeneous group of tumors with poor outcome. Recently, MIBC molecular subtyping efforts from an international con...

Chargement des enrichissements...